COVID-19 Vaccine Candidate Developed By China's CanSino, Gets First Invention Patent
CanSino said in a statement on Sunday that the grant of the patent further confirmed the vaccine¡¯s efficacy and safety and convincingly demonstrated the ownership of its intellectual property rights (IPR).
China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported.
The Ad5-nCoV vaccine already has approval for use by China¡¯s military, after early and mid-stage trials, and further late-stage trials are being lined up for Mexico and Saudi Arabia.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday.
The paper cited documents published by China's National Intellectual Property Administration, saying that the patent was issued on August 11.
Also Read: Amid Fear Of Moving Too Fast, Russia Produces First Batch Of COVID-19 Vaccine Sputnik V
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
A document published on China¡¯s National Intellectual Property Administration website said the vaccine can be mass-produced in a short time in the event of an outbreak, reported CGTN.
Also Read: India's First COVID-19 Vaccine 'COVAXIN' Appears Safe In Early Trials, Phase 2 Begins In Sept
CanSino and compatriots including Sinovac Biotech Ltd and China National Pharmaceutical Group Co Ltd (Sinopharm) are testing candidates overseas, as China becomes less conducive for Phase 3 trials due to its small number of new COVID-19 cases.
The completion of Phase 3 trials is generally required for regulatory approval to distribute a vaccine for public use.
Saudi Arabia plans to test the vaccine alongside a placebo on 5,000 volunteers and is currently preparing trials in the cities of Riyadh, Dammam and Mecca, Saudi state news agency SPA had reported.
All Inputs Reuters